Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Research and Development Expenses and Reimbursements Due

Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the three months ended March 31, 2017 and 2016, is presented as follows (dollars in thousands):

	Three Months Ended March 31,
	2017		2016
Research and development expense, gross	$	4,039	$	4,962
Less: Reimbursement of research and development expense	19		219
Research and development expense, net of reimbursements	$	4,020	$	4,743

Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding

The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

	March 31,
	2017	2016
Warrants to purchase Series C-1 Preferred	14,033	14,033
Warrants to purchase common stock associated with Loan Agreement	122,435	—
Stock options	2,770,029	1,450,453